Dose-Dependent Inhibitory Effect of Rosuvastatin in Japanese Patients with Acute Myocardial Infarction on Serum Concentration of Matrix Metalloproteinases–INVITATION Trial–
-
- Shirakawa Takuhiro
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, and Center for Metabolic Regulation of Healthy Aging (CMHA), Kumamoto University Department of Cardiovascular Medicine, Fukuoka Tokushukai Medical Center
-
- Fujisue Koichiro
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, and Center for Metabolic Regulation of Healthy Aging (CMHA), Kumamoto University
-
- Nakamura Shinichi
- Division of Cardiology, Japan Community Health care Organization Hitoyoshi Medical Center
-
- Yamamoto Nobuyasu
- Division of Cardiology, Miyazaki Prefectural Nobeoka Hospital
-
- Oshima Shuichi
- Division of Cardiology, Kumamoto Central Hospital
-
- Matsumura Toshiyuki
- Division of Cardiology, Japan Labor Health and Welfare Organization Kumamoto Rosai Hospital
-
- Tsunoda Ryusuke
- Division of Cardiology, Japanese Red Cross Kumamoto Hospital
-
- Hirai Nobutaka
- Division of Cardiology, Kumamoto Regional Medical Center
-
- Koide Shunichi
- Division of Cardiology, Health Insurance Kumamoto General Hospital
-
- Tayama Shinji
- Division of Cardiology, Health Insurance Kumamoto General Hospital
-
- Kikuta Koichi
- Division of Cardiology, Shin-Beppu Hospital
-
- Hirose Toyoki
- Division of Cardiology, Minamata City General Hospital & Medical Center
-
- Maruyama Hideki
- Division of Cardiology, Minamata City General Hospital & Medical Center
-
- Fujimoto Kazuteru
- Department of Cardiology, National Hospital Organization Kumamoto Medical Center
-
- Kajiwara Ichiro
- Division of Cardiology, Arao Municipal Hospital
-
- Sakamoto Tomohiro
- Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center
-
- Nakao Koichi
- Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center
-
- Sakaino Naritsugu
- Division of Cardiology, Amakusa Medical Center
-
- Nagayoshi Yasuhiro
- Division of Cardiology, Aso Medical Center
-
- Hokamaki Jun
- Division of Cardiology, Tamana Central Hospital
-
- Shimomura Hideki
- Department of Cardiovascular Medicine, Fukuoka Tokushukai Medical Center
-
- Sakamoto Kenji
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, and Center for Metabolic Regulation of Healthy Aging (CMHA), Kumamoto University
-
- Yamamoto Eiichiro
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, and Center for Metabolic Regulation of Healthy Aging (CMHA), Kumamoto University
-
- Izumiya Yasuhiro
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, and Center for Metabolic Regulation of Healthy Aging (CMHA), Kumamoto University Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine
-
- Kaikita Koichi
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, and Center for Metabolic Regulation of Healthy Aging (CMHA), Kumamoto University
-
- Hokimoto Seiji
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, and Center for Metabolic Regulation of Healthy Aging (CMHA), Kumamoto University
-
- Ogawa Hisao
- National Cerebral and Cardiovascular Center
-
- Tsujita Kenichi
- Department of Cardiovascular Medicine, Graduate School of Medical Sciences, and Center for Metabolic Regulation of Healthy Aging (CMHA), Kumamoto University
Search this article
Abstract
<p>Aim: Matrix metalloproteinases (MMPs) play critical roles in acute myocardial infarction (AMI). This trial was conducted to determine the potential effects of higher-dose rosuvastatin on circulating MMP levels in patients with AMI. </p><p>Methods: This was a multicenter, open-label, 1:1 randomized, parallel-group study. Patients with AMI were randomly assigned to the appropriate-dose group (10 mg rosuvastatin once daily) or the low-dose group (2.5 mg rosuvastatin once daily) within 24 hours after percutaneous coronary intervention. MMP-2 and MMP-9 levels were measured on day 1 and at week 4, 12, and 24 after enrollment. The primary endpoint was the change in MMP levels at 24 weeks after enrollment. The secondary endpoints were change in MMP levels at day 1 and weeks 4 and 12 after enrollment. </p><p>Results: Between August 2017 and October 2018, 120 patients with AMI from 19 institutions were randomly assigned to either the appropriate-dose or the low-dose group. There were 109 patients who completed the 24-week follow-up. The primary endpoint for both MMP-2 and MMP-9 was not significantly different between the two groups. The change in the active/total ratio of MMP-9 at week 12 after baseline was significantly lower in the appropriate-dose group compared with the low-dose group (0.81 [−52.8–60.1]% vs. 70.1 [−14.5–214.2]%, P=0.004), while the changes in MMP-2 were not significantly different between the two groups during the study period. </p><p>Conclusions: This study could not demonstrate the superiority of appropriate-dose of rosuvastatin in inhibiting serum MMPs levels in patients with AMI. </p>
Journal
-
- Journal of Atherosclerosis and Thrombosis
-
Journal of Atherosclerosis and Thrombosis 29 (2), 229-241, 2022-02-01
Japan Atherosclerosis Society
